These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34999006)

  • 1. Biochemical and biophysical features of disease-associated tau mutants V363A and V363I.
    De Luigi A; Colombo L; Russo L; Ricci C; Bastone A; Cimini S; Tagliavini F; Rossi G; Cantù L; Del Favero E; Salmona M
    Biochim Biophys Acta Proteins Proteom; 2022 Mar; 1870(3):140755. PubMed ID: 34999006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. V363I and V363A mutated tau affect aggregation and neuronal dysfunction differently in C. elegans.
    Morelli F; Romeo M; Barzago MM; Bolis M; Mattioni D; Rossi G; Tagliavini F; Bastone A; Salmona M; Diomede L
    Neurobiol Dis; 2018 Sep; 117():226-234. PubMed ID: 29936232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical Properties of Pathology-Related Tau Species in Tauopathy Brains: An Extraction Protocol for Tau Oligomers and Aggregates.
    Sahara N; Kimura T
    Methods Mol Biol; 2018; 1779():435-445. PubMed ID: 29886548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of assembly of tau(273-284) and its ΔK280 mutant: an experimental and computational study.
    Larini L; Gessel MM; LaPointe NE; Do TD; Bowers MT; Feinstein SC; Shea JE
    Phys Chem Chem Phys; 2013 Jun; 15(23):8916-28. PubMed ID: 23515417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAPT mutations associated with familial tauopathies lead to formation of conformationally distinct oligomers that have cross-seeding ability.
    Bhopatkar AA; Bhatt N; Haque MA; Xavier R; Fung L; Jerez C; Kayed R
    Protein Sci; 2024 Sep; 33(9):e5099. PubMed ID: 39145409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features.
    Rossi G; Bastone A; Piccoli E; Morbin M; Mazzoleni G; Fugnanesi V; Beeg M; Del Favero E; Cantù L; Motta S; Salsano E; Pareyson D; Erbetta A; Elia AE; Del Sorbo F; Silani V; Morelli C; Salmona M; Tagliavini F
    Neurobiol Aging; 2014 Feb; 35(2):408-17. PubMed ID: 24018212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
    Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resonance Raman spectroscopic measurements delineate the structural changes that occur during tau fibril formation.
    Ramachandran G; Milán-Garcés EA; Udgaonkar JB; Puranik M
    Biochemistry; 2014 Oct; 53(41):6550-65. PubMed ID: 25284680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
    Strang KH; Croft CL; Sorrentino ZA; Chakrabarty P; Golde TE; Giasson BI
    J Biol Chem; 2018 Feb; 293(7):2408-2421. PubMed ID: 29259137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice.
    Terwel D; Lasrado R; Snauwaert J; Vandeweert E; Van Haesendonck C; Borghgraef P; Van Leuven F
    J Biol Chem; 2005 Feb; 280(5):3963-73. PubMed ID: 15509565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.
    Ward SM; Himmelstein DS; Ren Y; Fu Y; Yu XW; Roberts K; Binder LI; Sahara N
    Neurobiol Dis; 2014 Jul; 67():37-48. PubMed ID: 24631720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy.
    Eckermann K; Mocanu MM; Khlistunova I; Biernat J; Nissen A; Hofmann A; Schönig K; Bujard H; Haemisch A; Mandelkow E; Zhou L; Rune G; Mandelkow EM
    J Biol Chem; 2007 Oct; 282(43):31755-65. PubMed ID: 17716969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotoxicity of oligomers of phosphorylated Tau protein carrying tauopathy-associated mutation is inhibited by prion protein.
    Nieznanska H; Boyko S; Dec R; Redowicz MJ; Dzwolak W; Nieznanski K
    Biochim Biophys Acta Mol Basis Dis; 2021 Nov; 1867(11):166209. PubMed ID: 34246750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.
    Koller EJ; Gonzalez De La Cruz E; Machula T; Ibanez KR; Lin WL; Williams T; Riffe CJ; Ryu D; Strang KH; Liu X; Janus C; Golde TE; Dickson D; Giasson BI; Chakrabarty P
    Hum Mol Genet; 2019 Oct; 28(19):3255-3269. PubMed ID: 31261380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.
    Lo CH; Lim CK; Ding Z; Wickramasinghe SP; Braun AR; Ashe KH; Rhoades E; Thomas DD; Sachs JN
    Alzheimers Dement; 2019 Nov; 15(11):1489-1502. PubMed ID: 31653529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tauopathies and tau oligomers.
    Takashima A
    J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain.
    Caillierez R; Bégard S; Lécolle K; Deramecourt V; Zommer N; Dujardin S; Loyens A; Dufour N; Aurégan G; Winderickx J; Hantraye P; Déglon N; Buée L; Colin M
    Mol Ther; 2013 Jul; 21(7):1358-68. PubMed ID: 23609018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational diversity of wild-type Tau fibrils specified by templated conformation change.
    Frost B; Ollesch J; Wille H; Diamond MI
    J Biol Chem; 2009 Feb; 284(6):3546-51. PubMed ID: 19010781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggregation Kinetics and Filament Structure of a Tau Fragment Are Influenced by the Sulfation Pattern of the Cofactor Heparin.
    Townsend D; Fullwood NJ; Yates EA; Middleton DA
    Biochemistry; 2020 Oct; 59(41):4003-4014. PubMed ID: 32954725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau and tauopathies.
    Lee G; Leugers CJ
    Prog Mol Biol Transl Sci; 2012; 107():263-93. PubMed ID: 22482453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.